AEON Biopharma Gets NYSE Notice Over $55M Equity Deficit, Listing Plan Extended
AEON Biopharma received a March 31, 2026 NYSE American notice for non-compliance with Section 1003(a)(ii) due to a $55 million stockholders’ deficit and losses in three of its four most recent fiscal years. Its stock will continue trading with a .BC indicator under its compliance plan through August 3, 2026.
1. Additional Listing Standard Notice
On March 31, 2026 AEON Biopharma received a notice from NYSE American indicating non-compliance with Section 1003(a)(ii) of the listing standards. This follows the Original Notice on non-compliance with Section 1003(a)(i) and reflects the progression of its compliance status.
2. Stockholders’ Deficit and Loss History
The notice cites AEON’s reported stockholders’ deficit of approximately $55 million as of December 31, 2025, and net losses from continuing operations in three of its four most recent fiscal years. The company’s current deficit level triggers the higher $4.0 million equity requirement under Section 1003(a)(ii).
3. Compliance Plan Timeline and Risks
AEON continues to operate under the approved plan with a deadline of August 3, 2026 to regain compliance. If compliance is not achieved or substantial progress is not made, delisting proceedings may be initiated, though the company retains the right to appeal any staff determination.